Fierce Medtech names Tasso as one of its “Fierce 15” Med Tech Companies of 2021

SEATTLE – March 7, 2022 – Tasso, Inc., a leader in clinical-grade blood collection technology, today announced that it has been named by Fierce Medtech as one of 2021’s Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.   

Tasso’s signature blood collection products and services are currently in use worldwide for a variety of healthcare, pharma, and research applications. The simple, patient-centric technology enables convenient remote collection of clinical grade blood, eliminating clinic access challenges. The combination of Tasso’s innovative, virtually painless blood collection technology with an integrated logistics platform empowers pharmaceutical companies, academic institutions, and payers to expand their home health operations. 

“The COVID-19 pandemic has led to a fundamental shift in how we think about healthcare, and demand for patient-centric, in-home solutions is greater than ever,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “To be recognized as one of the 2021 Fierce 15 Med Tech Companies is a tremendous honor and another strong validation of our team and technology. We will continue to build on this momentum and enable more people worldwide to benefit from streamlined access to clinical diagnostics.” 

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.  This is Fierce Medtech’s 10th annual Fierce 15 selection.   This year’s full list of winners can be viewed online at www.fiercebiotech.com/special-reports/fierce-medtechs-2021-fierce-15

“While we’re not fully out of the woods yet when it comes to COVID-19, the innovations pursued by this year’s class of 15 companies will help the industry evolve, either in step with the pandemic or in spite of it,” said Conor Hale, senior editor of Fierce Medtech. 

An internationally recognized daily report reaching a network of over 90,000 med tech industry professionals, Fierce Medtech provides subscribers with an authoritative analysis of the day's top stories. Every year Fierce Medtech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position. 

 

About Fierce Medtech 

Fierce Medtech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology.  More than 90,000 top industry professionals rely on Fierce Medtech for an insider briefing on the day's top stories. 

 

About Tasso 

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com .

 

CONTACTS: 

Rebecca Willumson 

Fierce Medtech 

(202) 824-5050 

rwillumson@questex.com 

 

Dina Schneider 

Tasso, Inc. 

(206) 822-4186 x1016 

media@tassoinc.com 

Previous
Previous

Tasso Launches Integrated Population Pharmacokinetic Solutions to Optimize, Scale, and Accelerate Decentralized Clinical Trials

Next
Next

Vault Health and Tasso Partner for Expansion of Patient-Centric At-Home Diagnostics